Drug-Linker-Conjugates-for-ADC-Inhibitors-Modulators-MCE

1、 HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html Drug-Linker HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html Conjugates HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html HYPERLIN

2、K https:/www.MedChemE/Targets/Antibody-drug Conjugate.html for HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html ADCDrug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and

3、an appropriate linker. Afterlinked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells withhigh selectivity and cytotoxicity.The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor a

4、ctivity and can beclassified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs areDuocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors areAuristatins and Maytansinoids. Besides, there

5、are also many traditional cytotoxic agents can be used in ADCs.ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavablelinkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteo

6、lytic degradation of theantibody portion of the ADC for release of the cytotoxic molecule.www.MedChemE 1 HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html Drug-Linker HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html HYPERLINK https:/www.MedChemE/Targets/Antibody-dr

7、ug Conjugate.html Conjugates HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html for HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html

8、 ADC HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html Inhibitors HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html & HYPERLINK http

9、s:/www.MedChemE/Targets/Antibody-drug Conjugate.html HYPERLINK https:/www.MedChemE/Targets/Antibody-drug Conjugate.html Chemicals HYPERLINK https:/www.MedChemE/rac-lys-smcc-dm1.html (Rac)-Lys-SMCC-DM1(Rac)-Lys-N-MCC-DM1) Cat. No.: HY-101982A HYPERLINK https:/www.MedChemE/2-3-cgamp-c2-ppa.html 2,3-cG

10、AMP-C2-PPACat. No.: HY-141662(Rac)-Lys-SMCC-DM1 (Rac)-Lys-N-MCC-DM1) is theracemate of Lys-SMCC-DM1 (HY-101982). Lys-SMCC-DM1is a linker-payload component that has thepotential to inhibit tubulin polymerization.Lys-SMCC-DM1 is the active metabolite of T-DM1.2,3-cGAMP-C2-PPA (45), A cyclic di-nucleot

11、ide,is a STING agonist (US20210015941A1).2,3-cGAMP-C2-PPA is a drug-linker conjugatefor ADC that can be used in synthesis ofantibody-drug conjugates for the targetedtreatment of cancer.Purity: 98.18%Clinical Data: No Development ReportedSize: 1 mg, 5 mg, 10 mgPurity: 98%Clinical Data: No Development

12、 ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/Acetylene-linker-Val-Cit-PABC-MMAE.html Acetylene-linker-Val-Cit-PABC-MMAE(LCB14-0602) Cat. No.: HY-19812 HYPERLINK https:/www.MedChemE/AcLys-PABC-VC-Aur0101.html AcLys-PABC-VC-Aur0101Cat. No.: HY-111554Acetylene-linker-Val-Cit-PABC-MMAE (LCB14

13、-0602)consists the ADCs linker(Acetylene-linker-Val-Cit-PABC) and potent tubulininhibitor (MMAE).Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) isa drug-linker conjugate for ADC.AcLys-PABC-VC-Aur0101 is a drug-linker conjugatefor ADC (anti-CXCR4 ADC) with potent antitumoractivity by using Aur0101 (

14、an auristatinmicrotubule inhibitor), linked via the cleavablelinker AcLys-PABC-VC.Purity: 95.08Clinical Data: No Development ReportedSize: 1 mg, 5 mg, 10 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/SW-163D-AcLysValCit-PABC-DMAE.html AcLysValCit-P

15、ABC-DMAE-SW-163D HYPERLINK https:/www.MedChemE/SW-163D-AcLysValCit-PABC-DMAE.html HYPERLINK https:/www.MedChemE/aminobenzenesulfonic-auristatin-e.html Aminobenzenesulfonic HYPERLINK https:/www.MedChemE/aminobenzenesulfonic-auristatin-e.html HYPERLINK https:/www.MedChemE/aminobenzenesulfonic-auristat

16、in-e.html auristatin HYPERLINK https:/www.MedChemE/aminobenzenesulfonic-auristatin-e.html HYPERLINK https:/www.MedChemE/aminobenzenesulfonic-auristatin-e.html ECat. No.: HY-114325 Cat. No.: HY-145989AcLysValCit-PABC-DMAE-SW-163D is a drug-linkerconjugates for ADC which consists of a naturalbis-inter

17、calator, SW-163D, conjugated via anAcLysValCitPABC-DMAE linker.Aminobenzenesulfonic auristatin E is a drug-linkerconjugate for ADC with potent antitumor activityby using Auristatin E (a cytotoxic tubulinmodifier), linked via the ADC linkerAminobenzenesulfonic.Purity: 98%Clinical Data: No Development

18、 ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/aminooxy-catb-lxr.html Aminooxy HYPERLINK https:/www.MedChemE/aminooxy-catb-lxr.html HYPERLINK https:/www.MedChemE/aminooxy-catb-lxr.html CatB-LXR HYPERLINK https:/www.MedChemE/am

19、inooxy-catb-lxr.html HYPERLINK https:/www.MedChemE/AmPEG6C2-Aur0131.html AmPEG6C2-Aur0131Cat. No.: HY-144554 Cat. No.: HY-111555Aminooxy CatB-LXR (compound 10) is a drug-linkerconjugates for ADC.AmPEG6C2-Aur0131 is a drug-linker conjugate forADC (anti-CXCR4 ADC) with potent antitumoractivity by usin

20、g Aur0131 (an auristatinmicrotubule inhibitor), linked via thenon-cleavable linker AmPEG6C2.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/mc-lys-pabc.html AZ1508 HYPERLINK https:/www.Me

21、dChemE/mc-lys-pabc.html HYPERLINK https:/www.MedChemE/azide-peg4-vc-pab-doxorubicin.html Azide-PEG4-VC-PAB-Doxorubicin(MC-Lys-MMETA) Cat. No.: HY-128962Cat. No.: HY-136288AZ1508 is a drug-linker conjugates for ADC for thetreatment of breast and stomach cancer, and thedrug is a tubulin inhibitor.Azid

22、e-PEG4-VC-PAB-Doxorubicin is a drug-linkerconjugate composed of a cytotoxic anthracyclineantibiotic Doxorubicin and a linkerAzide-PEG4-VC-PAB to make antibody drug conjugate(ADC).Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1

23、 mg, 5 mg2 Tel: 609-228-6898 Fax: 609-228-5909 Email: salesMedChemE HYPERLINK https:/www.MedChemE/azido-peg4-val-cit-pab-mmae.html Azido-PEG4-Val-Cit-PAB-MMAE HYPERLINK https:/www.MedChemE/azido-peg4-val-cit-pab-mmae.html HYPERLINK https:/www.MedChemE/bi-mc-vc-pab-mmae.html Bi-Mc-VC-PAB-MMAECat. No.

24、: HY-W190943 Cat. No.: HY-141833Azido-PEG4-Val-Cit-PAB-MMAE is a drug-linkerconjugate for ADC by using the anti-mitotic agent,monomethyl auristatin E (MMAE, a tubulininhibitor), linked via the cleavable linkerAzido-PEG4-Val-Cit-PAB-OH.Bi-Mc-VC-PAB-MMAE consists ADCs linker(Fmoc-Val-Cit-PAB) and pote

25、nt tubulin inhibitor(MMAE). Bi-Mc-VC-PAB-MMAE is a drug-linkerconjugate for ADC.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg, 10 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/cck2r-ligand-crl.html CCK2R HYPERLINK https:/www.Med

26、ChemE/cck2r-ligand-crl.html HYPERLINK https:/www.MedChemE/cck2r-ligand-crl.html Ligand-Linker HYPERLINK https:/www.MedChemE/cck2r-ligand-crl.html HYPERLINK https:/www.MedChemE/cck2r-ligand-crl.html Conjugates HYPERLINK https:/www.MedChemE/cck2r-ligand-crl.html HYPERLINK https:/www.MedChemE/cck2r-lig

27、and-crl.html 1 HYPERLINK https:/www.MedChemE/cck2r-ligand-crl.html HYPERLINK https:/www.MedChemE/cl2-sn-38.html CL2-SN-38Cat. No.: HY-128941 Cat. No.: HY-126350CCK2R Ligand-Linker Conjugates 1 is aligand-linker conjugate, which conjugates to thecytotoxic antimicrotubule agents DesacetylVinblastine H

28、ydrazide (DAVBH) and Tubulysin BHydrazide (TubBH) via a hydrophilic peptidelinker.CL2-SN-38 is a part of the antibody drug conjugate(ADC), can conjugate with theanti-Trop-2-humanized antibody hRS7. SN-38 is aDNA topoisomerase I inhibitor.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5

29、 mgPurity: 98%Clinical Data: No Development ReportedSize: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/cl2a-sn-38.html CL2A-SN-38 HYPERLINK https:/www.MedChemE/cl2a-sn-38.html HYPERLINK https:/www.MedChemE/cl2e-sn38.html CL2E-SN38Cat. No.: HY-128946 Cat. No.: HY-139909CL2A-SN-38 i

30、s a drug-linker conjugate composed ofa potent a DNA Topoisomerase I inhibitor SN-38 anda linker CL2A to make antibody drug conjugate(ADC). CL2A-SN-38 provides significant andspecific antitumor effects against a range ofhuman solid tumor types.CL2E-SN-38, a highly releasable and structurallystable an

31、tibody-SN-38-conjugate, is a part ofthe antibody drug conjugate (ADC). SN-38,the active metabolite of Irinotecan fromcamptothecins, is an TopoisomeraseI inhibitor.Purity: 98.64%Clinical Data: No Development ReportedSize: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgPurity: 98%Clinical Data: No Development

32、 ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/cl2e-sn38-tfa.html CL2E-SN38 HYPERLINK https:/www.MedChemE/cl2e-sn38-tfa.html HYPERLINK https:/www.MedChemE/cl2e-sn38-tfa.html TFA HYPERLINK https:/www.MedChemE/cl2e-sn38-tfa.html HYPERLINK https:/www.MedChemE/cys-mcmmad.html Cys-mcMMADCat. No.

33、: HY-139909A Cat. No.: HY-15750CL2E-SN-38 TFA, a highly releasable andstructurally stable antibody-SN-38-conjugate, is apart of the antibody drug conjugate (ADC).SN-38, the active metabolite of Irinotecan fromcamptothecins, is an TopoisomeraseI inhibitor.Cys-mcMMAD is a drug-linker conjugate for ADC

34、.MMAD is a potent tubulin inhibitor.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg HYPERLINK https:/www.MedChemE/spdb-linker.html DBA-DM4 HYPERLINK https:/www.MedChemE/spdb-linker.html HYPERLINK https:/www.MedChemE/DBCO-_P

35、EG_3-VC-PAB-MMAE.html DBCO-(PEG)3-VC-PAB-MMAECat. No.: HY-128960 Cat. No.: HY-111012DBA-DM4 is a drug-linker conjugate composed of apotent a tubulin inhibitor DM1 and a linker SPDPto make antibody drug conjugate (ADC).DBCO-(PEG)3-VC-PAB-MMAE is made by MMAEconjugated to DBCO-(PEG)3-vc-PAB linker.Mon

36、omethyl auristatin E (MMAE), a potent tubulininhibitor, is a toxin payload in antibody drugconjugate.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 5 mg (1 mg x 5), 10 mg (1 mg x 10), 1 mgwww.MedChemE 3 HYPERLINK https:/www.Med

37、ChemE/dbco-peg2-vc-pab-mmae-2.html DBCO-(PEG2-VC-PAB-MMAE)2 HYPERLINK https:/www.MedChemE/dbco-peg2-vc-pab-mmae-2.html HYPERLINK https:/www.MedChemE/dbco-peg4-ahx-dm1.html DBCO-PEG4-Ahx-DM1Cat. No.: HY-126690 Cat. No.: HY-136260DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAEconjugated to the cleavable DBCO

38、-(PEG2-VC-PAB)2linker. Monomethyl auristatin E (MMAE), a potenttubulin inhibitor, is a toxin payload in antibodydrug conjugate.DBCO-PEG4-Ahx-DM1 is a drug-linker conjugatecomposed of a potentmicrotubulin inhibitor DM1 and a linkerDBCO-PEG4-Ahx to make antibody drug conjugate(ADC).Purity: 98%Clinical

39、 Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/dbco-peg4-ggfg-dx8951.html DBCO-PEG4-GGFG-DX8951 HYPERLINK https:/www.MedChemE/dbco-peg4-ggfg-dx8951.html HYPERLINK https:/www.MedChemE/dbco-peg4-mmaf.html DB

40、CO-PEG4-MMAFCat. No.: HY-134723 Cat. No.: HY-133492DBCO-PEG4-GGFG-DX8951 is a drug-linker conjugatefor ADC with potent antitumor activity by usingDX8951 (a DNA topoisomerase I inhibitor), linkedvia the non-cleavable ADC linker DBCO-PEG4-GGFG.DBCO-PEG4-MMAF is a drug-linker conjugate for ADCwith pote

41、nt antitumor activity by using thetubulin polymerization inhibitor, MMAF, linked viathe cleavable linker DBCO-PEG4.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 10 mg HYPERLINK https:/www.MedChemE/dbco-peg4-va-pbd.html DBCO-PE

42、G4-VA-PBD HYPERLINK https:/www.MedChemE/dbco-peg4-va-pbd.html HYPERLINK https:/www.MedChemE/dbco-peg4-val-cit-pab-mmaf.html DBCO-PEG4-Val-Cit-PAB-MMAFCat. No.: HY-133433 Cat. No.: HY-130990DBCO-PEG4-VA-PBD is a drug-linker conjugate forADC by using the antitumor antibiotic,Pyrrolobenzodiazepine (PBD

43、), linked viaDBCO-PEG4-VA.DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and apotent tubulin polymerization inhibitor (MMAF).DBCO-PEG4-Val-Cit-PAB-MMAF can be used in thesynthesis of antibody-drug conjugates (ADCs).Purity: 98%Clinical Data: No Developmen

44、t ReportedSize: 1 mg, 5 mg, 10 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/dbco-peg4-vc-pab-dmea-pnu-159682.html DBCO-PEG4-VC-PAB-DMEA-PNU-159682 HYPERLINK https:/www.MedChemE/dbco-peg4-vc-pab-dmea-pnu-159682.html HYPERLINK https:/www.MedChemE/db

45、co-peg4-vc-pab-mmae.html DBCO-PEG4-VC-PAB-MMAECat. No.: HY-126691 Cat. No.: HY-136314DBCO-PEG4-VC-PAB-DMEA-PNU-159682, adrug-linker conjugate for ADC, consists theADC linker DBCO-PEG4-VC-PAB and a potent ADCcytotoxin DMEA-PNU-159682. DMEA-PNU-159682includes metabolites of nemorubicin (MMDX) fromlive

46、r microsomes and ADC cytotoxin PNU-159682.DBCO-PEG4-VC-PAB-MMAE consistsa ADC linker (DBCO-PEG4-VC-PAB) and atubulin polymerization inhibitor MMAE(HY-15162). DBCO-PEG4-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).Purity: 98%Clinical Data: No Development ReportedSize: 5

47、 mg, 10 mg, 25 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/dbm-mmaf.html DBM-MMAF HYPERLINK https:/www.MedChemE/dbm-mmaf.html HYPERLINK https:/www.MedChemE/Deruxtecan_analog.html DeruxtecanCat. No.: HY-136287 Cat. No.: HY-13631EDBM-MMAF is a drug

48、-linker conjugate composed of apotent antitubulin agent MMAF and a linker DBM tomake antibody drug conjugate (ADC).Deruxtecan is an ADC drug-linker conjugatecomposed of a derivative of DX-8951 (DXd) and amaleimide-GGFG peptide linker, used forsynthesizing DS-8201 and U3-1402.Purity: 98%Clinical Data

49、: No Development ReportedSize: 1 mg, 5 mgPurity: 99.43%Clinical Data: Phase 3Size: 1 mg, 5 mg, 10 mg4 Tel: 609-228-6898 Fax: 609-228-5909 Email: salesMedChemE HYPERLINK https:/www.MedChemE/desmethyl-vc-seco-duba.html Desmethyl HYPERLINK https:/www.MedChemE/desmethyl-vc-seco-duba.html HYPERLINK https

50、:/www.MedChemE/desmethyl-vc-seco-duba.html Vc-seco-DUBA HYPERLINK https:/www.MedChemE/desmethyl-vc-seco-duba.html HYPERLINK https:/www.MedChemE/dgn549-c.html DGN549-CCat. No.: HY-131085 Cat. No.: HY-136297Desmethyl Vc-seco-DUBA consists a cleavable ADClinker (Desmethyl Vc-seco) and a DNA alkylatinga

51、gent (DUBA). Desmethyl Vc-seco-DUBA can be usedin the synthesis of antibody-drug conjugates(ADCs).DGN549-C consists a cleavable ADC linkervaline-alanine (va) and PBD dimer. DGN549 is anovel DNA-alkylating cytotoxic payload and can beused in the synthesis of antibody-drug conjugates (ADCs).Purity: 98

52、%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/dgn549-l.html DGN549-L HYPERLINK https:/www.MedChemE/dgn549-l.html HYPERLINK https:/www.MedChemE/dm1-peg4-dbco.html DM1-PEG4-DBCOCat. No.: HY-145365

53、Cat. No.: HY-136261DGN549-L is a DNA alkylator and can be utilizedfor antibody conjugation at lysine residues.DGN549-L can be used in the synthesis ofantibody-drug conjugates (ADCs).DM1-(PEG)4-DBCO is a drug-linker conjugatecomposed of a potentmicrotubulin inhibitor DM1 and a linkerDBCO-PEG4-Ahx to

54、make antibody drug conjugate(ADC).Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/dm4-smcc.html DM4-SMCC HYPERLINK https:/www.MedChemE/dm4-smcc.html HYPERLINK https:/www.MedChemE/dm4-spdp

55、.html DM4-SPDPCat. No.: HY-126494 Cat. No.: HY-126493DM4-SMCC is a drug-linker conjugate for ADC withantitumor activity by using DM4 (an antitubulinagent), linked via the non-cleavable SMCC linker.DM4-SPDP is a drug-linker conjugate composed of apotent antitubulin agent DM4 and a linker SMCC tomake

56、antibody drug conjugate.Purity: 98%Clinical Data: No Development ReportedSize: 10 mg, 25 mg, 50 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/doxorubicin-smcc.html Doxorubicin-SMCC HYPERLINK https:/www.MedChemE/doxorubicin-smcc.html HYPERLINK https

57、:/www.MedChemE/st8154aa1.html FCHFHS-ST7612AA1Cat. No.: HY-116063 Cat. No.: HY-112805Doxorubicin-SMCC is a drug-linker conjugate forADC. Doxorubicin-SMCC contains a non-cleavableADC linker and a DNA topoisomerase II inhibitorDoxorubicin.FCHFHS-ST7612AA1 is a part of antibody drugconjugates (ADCs) ch

58、arged with HDAC inhibitor bya linker, shows antitumor activity.Purity: 99.48%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/fmoc-val-cit-pab-duocarmycin-tm.html F

59、moc-Val-Cit-PAB-Duocarmycin HYPERLINK https:/www.MedChemE/fmoc-val-cit-pab-duocarmycin-tm.html HYPERLINK https:/www.MedChemE/fmoc-val-cit-pab-duocarmycin-tm.html TM HYPERLINK https:/www.MedChemE/fmoc-val-cit-pab-duocarmycin-tm.html HYPERLINK https:/www.MedChemE/Fmoc-Val-Cit-PAB-MMAE.html Fmoc-Val-Ci

60、t-PAB-MMAECat. No.: HY-126532 Cat. No.: HY-19811Fmoc-Val-Cit-PAB-Duocarmycin TM is a drug-linkerconjugate for ADC by using the antitumorantibiotic, Duocarmycin TM, linked viaFmoc-Val-Cit-PAB.Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker(Fmoc-Val-Cit-PAB) and potent tubulin inhibitor(MMAE). Fmoc-Val